Perspective Therapeutics (NYSEAMERICAN:CATX) Hits New 12-Month High at $1.87

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) shares hit a new 52-week high on Thursday . The stock traded as high as 1.87 and last traded at 1.80, with a volume of 1132979 shares trading hands. The stock had previously closed at 1.70.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. B. Riley upped their price target on shares of Perspective Therapeutics from $1.20 to $1.70 and gave the stock a “buy” rating in a research report on Tuesday, April 9th. Oppenheimer restated an “outperform” rating and set a $1.50 price objective (up from $1.20) on shares of Perspective Therapeutics in a report on Monday, April 1st.

Perspective Therapeutics Trading Up 4.6 %

The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.07 and a current ratio of 1.07. The company has a market capitalization of $1.06 billion, a PE ratio of -18.10 and a beta of 1.43.

Insider Activity

In related news, major shareholder Lantheus Alpha Therapy, Llc acquired 60,431,039 shares of the company’s stock in a transaction on Wednesday, March 6th. The shares were purchased at an average price of 0.95 per share, for a total transaction of 57,409,487.05. Following the purchase, the insider now owns 116,773,394 shares in the company, valued at 110,934,724.30. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 3.52% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Perspective Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. ZWJ Investment Counsel Inc. acquired a new position in Perspective Therapeutics during the first quarter worth $26,000. Simplicity Wealth LLC acquired a new position in shares of Perspective Therapeutics during the 1st quarter valued at about $40,000. Taylor & Morgan Wealth Management LLC raised its stake in shares of Perspective Therapeutics by 8.7% in the 4th quarter. Taylor & Morgan Wealth Management LLC now owns 625,000 shares of the company’s stock valued at $251,000 after acquiring an additional 50,000 shares in the last quarter. RIA Advisory Group LLC lifted its holdings in Perspective Therapeutics by 1,313.4% in the 1st quarter. RIA Advisory Group LLC now owns 106,853 shares of the company’s stock worth $127,000 after purchasing an additional 99,293 shares during the last quarter. Finally, Bank of New York Mellon Corp bought a new stake in Perspective Therapeutics during the third quarter worth approximately $42,000. Institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.